Tagged with Research

Puerto Rico Dr. Eduardo Nicolau shares his journey from being a professor of chemistry to becoming Executive Director of the MSRC in 2021. His leadership focuses on financial stability, creating a biotech incubator, and establishing key partnerships with the industry, including a significant collaboration with the biotechnology company CytoImmune Therapeutics for cancer…

Spain A roundup of some of the top stories coming out of Spain’s life sciences sector, including Brookfield’s ongoing interest in Grifols; Rovi’s change of heart about selling its CDMO business; Reig Jofre’s partnership with startup DyCare for an AI-powered digital rehabilitation platform; Almirall’s European filing for its triazole antifungal compound;…

Puerto Rico Lucy Crespo, CEO of the Puerto Rico Science Technology and Research Trust, highlights significant recent advancements in establishing Puerto Rico as a global innovation hub, including the recent designation of Puerto Rico as one of the US Economic Development Administration’s technology hubs (Tech Hubs) and the opening of the island’s…

Puerto Rico Ivan Lugo-Montes emphasizes the Puerto Rico Bioscience Cluster (INDUNIV)’s instrumental role in advancing the island’s biosciences industry for over 60 years. Driven by innovation, workforce development, and global competitiveness, the Cluster has achieved significant milestones in advanced manufacturing, pharmaceutical cold chain logistics certification, business promotion, and international partnerships. Key initiatives…

Mexico Arturo Rodriguez, CEO of Infinite Clinical Research, discusses the current state of clinical trials in Mexico and highlights the country’s unique advantages, such as a diverse population with experienced medical professionals and top-notch medical facilities. He addresses the challenges of streamlining regulatory processes and the need for improvements to attract…

Global Contract research organisations (CROs) have proven to be increasingly vital partners for the global biopharmaceutical industry guaranteeing efficient and compliant clinical trials that help to advance their candidates towards regulatory approvals. CROs have also demonstrated their ability to adapt to the industry’s changing needs by enlarging their geographical reach and…

Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…

Global The US National Institutes of Health (NIH) is the largest public investor in HIV/AIDS research globally. This means that, as Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy & Infectious Diseases (NIAID) Dr Carl Dieffenbach oversees a global HIV/AIDS research portfolio of more than…

UK Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the Coalition for Epidemic Preparedness Innovation (CEPI). In January he took on the leadership of the UK-based foundation Wellcome, coinciding with…

India Dr Suresh Advani, director of the department of Medical Oncology at Jaslok Hospital and Research Centre reviews the progress of medical oncology in India and talks over the significant contribution of the hospital to the field with its involvement in large international clinical trials, particularly phase I trials. He laments…

India India’s National Chemical Laboratory (NCL), one of the most well-established labs in the wider Council of Scientific and Industrial Research (CSIR) network, has made some major contributions to improving the country’s manufacturing processes for pharmaceutical intermediates and APIs. Director Dr Ashish Lele outlines the approaches the lab is pursuing, such…

France France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such as the National Health Data System contribute to France’s competitiveness, obstacles to further growth remain. In conversation with PharmaBoardroom, Hubert…